Elodie Labeille1, Carole Burillon1, Pierre-Loïc Cornut2. 1. From the Departments of Ophthalmology, L. Hussel Hospital (Labeille, Cornut), Vienne, Hospices Civils de Lyon (Burillon, Cornut), E. Herriot Hospital, University of Lyon 1 Claude Bernard, Lyon, and Pole Vision Val d'Ouest (Cornut), Ecully, France. 2. From the Departments of Ophthalmology, L. Hussel Hospital (Labeille, Cornut), Vienne, Hospices Civils de Lyon (Burillon, Cornut), E. Herriot Hospital, University of Lyon 1 Claude Bernard, Lyon, and Pole Vision Val d'Ouest (Cornut), Ecully, France. Electronic address: dr.cornut@gmail.com.
Abstract
PURPOSE: To assess the medium-term efficacy and safety of treating nucleus and intraocular lens (IOL) dislocation with pars plana vitrectomy (PPV) combined with iris-claw IOL implantation. SETTING: Department of Ophthalmology, University of Lyon 1 Claude Bernard, Lyon, France. DESIGN: Retrospective case series. METHODS: The study comprised consecutive patients without capsule support having PPV combined with iris-claw IOL implantation for posterior dislocation of the nucleus or IOL between 2008 and 2012. The preoperative, intraoperative, and postoperative data were retrospectively analyzed. Patients were invited to a prospective final examination at least 6 months postoperatively. RESULTS: The study enrolled 32 eyes (31 consecutive patients). The dislocation was spontaneous in 8 cases and traumatic in 24 (intraoperative 17 cases, contusive 7 cases). The iris-claw IOL was on the anterior side of the iris in 19 cases and on the posterior side in 13 cases. The mean corrected distance visual acuity at the end of follow-up was 20/40 or better in 22 patients (69%). The mean spherical equivalent was +8.20 (SD)±6.03 diopters (D) preoperatively and -0.51±1.14 D postoperatively. The median endothelial cell loss was 20.5% over the first 3 months. The complications were cystoid macular edema (n=8), retinal detachment (n=4), transient intravitreal hemorrhage (n=4), secondary glaucoma (n=2), and choroidal detachment (n=1). The final examination was performed in 27 eyes. CONCLUSION: Treatment of nucleus and IOL dislocation with PPV combined with iris-claw IOL implantation was effective and safe over the medium-term. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
PURPOSE: To assess the medium-term efficacy and safety of treating nucleus and intraocular lens (IOL) dislocation with pars plana vitrectomy (PPV) combined with iris-claw IOL implantation. SETTING: Department of Ophthalmology, University of Lyon 1 Claude Bernard, Lyon, France. DESIGN: Retrospective case series. METHODS: The study comprised consecutive patients without capsule support having PPV combined with iris-claw IOL implantation for posterior dislocation of the nucleus or IOL between 2008 and 2012. The preoperative, intraoperative, and postoperative data were retrospectively analyzed. Patients were invited to a prospective final examination at least 6 months postoperatively. RESULTS: The study enrolled 32 eyes (31 consecutive patients). The dislocation was spontaneous in 8 cases and traumatic in 24 (intraoperative 17 cases, contusive 7 cases). The iris-claw IOL was on the anterior side of the iris in 19 cases and on the posterior side in 13 cases. The mean corrected distance visual acuity at the end of follow-up was 20/40 or better in 22 patients (69%). The mean spherical equivalent was +8.20 (SD)±6.03 diopters (D) preoperatively and -0.51±1.14 D postoperatively. The median endothelial cell loss was 20.5% over the first 3 months. The complications were cystoid macular edema (n=8), retinal detachment (n=4), transient intravitreal hemorrhage (n=4), secondary glaucoma (n=2), and choroidal detachment (n=1). The final examination was performed in 27 eyes. CONCLUSION: Treatment of nucleus and IOL dislocation with PPV combined with iris-claw IOL implantation was effective and safe over the medium-term. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Authors: G Jayamadhury; Sudhakar Potti; K Vinaya Kumar; R Madhu Kumar; K C Divyansh Mishra; Srinivasa Rao Nambula Journal: Indian J Ophthalmol Date: 2016-10 Impact factor: 1.848